Neuronetics (STIM) to Release Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Neuronetics to post earnings of ($0.13) per share and revenue of $29.07 million for the quarter.

Neuronetics Stock Performance

Shares of STIM opened at $4.45 on Tuesday. The company's 50 day moving average price is $4.25 and its 200 day moving average price is $2.62. Neuronetics has a 52 week low of $0.52 and a 52 week high of $5.92. The company has a market capitalization of $292.88 million, a PE ratio of -3.62 and a beta of 1.97. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16.

Analyst Ratings Changes

Separately, Canaccord Genuity Group boosted their price objective on shares of Neuronetics from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th.

Insider Activity at Neuronetics

In other Neuronetics news, CEO Keith J. Sullivan sold 40,992 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $134,453.76. Following the completion of the sale, the chief executive officer now directly owns 1,283,362 shares of the company's stock, valued at $4,209,427.36. The trade was a 3.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Stephen Furlong sold 17,307 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $4.11, for a total transaction of $71,131.77. Following the completion of the sale, the chief financial officer now directly owns 454,420 shares of the company's stock, valued at $1,867,666.20. This represents a 3.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 100,369 shares of company stock valued at $358,929. Corporate insiders own 9.80% of the company's stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.